News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

US-China Pharmaceutical Venture Ascletis, Inc. Receives Record-Level Research and Development Grant from Hangzhou


1/4/2012 8:40:12 AM

RESEARCH TRIANGLE PARK, N.C. & HANGZHOU, China--(BUSINESS WIRE)--Ascletis, Inc., a U.S.-China joint venture pharmaceutical company, today announced it has received a record level research and development grant from Hangzhou National Hi-Tech Industrial Development Zone (HHTZ) under that organization’s “5050 Plan.” The 10 million RMB grant (approximately US$1.6 million) is the largest startup company grant in the history of the 5050 Plan, whose goal is to incentivize and assist start-up, technology-based companies within HHTZ, Hangzhou, Zhejiang Province.

Read at BioSpace.com
Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES